Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU6R3O)

Drug Name

CLG561 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Geographic retinal atrophy	9B78.9	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement factor P (CFP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALXN1820	DMNZOJ3	Sickle-cell disorder	3A51	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02515942) CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA). U.S. National Institutes of Health.
2	Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342.
3	Clinical pipeline report, company report or official report of Alexion